EWTX — Edgewise Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE -Revolution Medicines, FedEx, Cummins
Edgewise surges on sale of muscle dystrophy business to Servier
Brief: Edgewise Therapeutics Announces Sale Of Sevasemten For Up To $2.65 Billion, Strengthening Balance Sheet And Centering Company Focus On Cardiovascular Pipeline
Brief: Edgewise Therapeutics Announces Sale Of Sevasemten To Servier For Up To $2.65 Bln
Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion
Edgewise Therapeutics Q1 net loss widens on higher R&D costs
Brief: Edgewise Therapeutics Q1 Operating Expenses USD 54.115 Million
Brief: Edgewise Therapeutics Reports Inducement Grants As Permitted By The Nasdaq Listing Rules
U.S. RESEARCH ROUNDUP- Biogen, Eli Lilly, Johnson & Johnson
Edgewise Therapeutics Q4 net loss widens vs Q3 as costs rise
Brief: Edgewise Therapeutics Q4 Operating Income USD -55.979 Million
Brief: Edgewise Therapeutics Provides Corporate Updates And Highlights Priorities For 2026
Brief: Edgewise Therapeutics Reports Inducement Grants As Permitted By The Nasdaq Listing Rules
Edgewise Therapeutics rises on positive safety data from heart disease drug trial
Brief: Edgewise Therapeutics Inc On Track To Deliver Full 12-Week Part D Readout In 2Q 2026 And Phase 3 Start In 4Q 2026
Brief: Edgewise Therapeutics Reports Inducement Grants As Permitted By The Nasdaq Listing Rules
Brief: Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin To Its Board Of Directors
U.S. RESEARCH ROUNDUP-Disney, Enanta Pharmaceuticals, Phillips 66
Edgewise Therapeutics Q3 net loss widens as R&D costs rise